Autopsy report · NCT03992131
A Study to Evaluate Rucaparib in Combination With Other Anticancer Agents in Participants With a Solid Tumor (SEASTAR)
Cause of deathFunding or business
“Due to a change in development priorities, no further clinical development of the lucitanib plus rucaparib or lucitanib plus sacituzumab govitecan combinations is planned at this time.”
Life of this trial
- Ran for about 2 years 10 months before it stopped.
- 25 participants enrolled.
- Results were posted on the registry 1 year 9 months after it ended.
Vital statistics
- Status
- Terminated
- Phase
- Phase 1, Phase 2
- Sponsor
- pharmaand GmbH
- Sponsor type
- Industry
- Conditions
- Ovarian Cancer; Triple-negative Breast Cancer; Urothelial Carcinoma; Solid Tumor
- Interventions
- Rucaparib; Lucitanib; Sacituzumab govitecan
- Participants
- 25
- Sites
- 3
- Countries
- United States
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.